减肥
医学
内科学
内分泌学
2型糖尿病
胰高血糖素样肽1受体
兴奋剂
胰高血糖素样肽-1
糖尿病
激素
艾塞那肽
2型糖尿病
胰高血糖素
胰岛素抵抗
胰岛素
胰腺
肥胖
受体
作者
Sulayman A. Lyons,Jacqueline L. Beaudry
出处
期刊:Endocrinology
[The Endocrine Society]
日期:2023-09-23
卷期号:164 (11)
标识
DOI:10.1210/endocr/bqad153
摘要
Abstract Metabolic diseases, such as obesity, type 2 diabetes mellitus (T2DM), cardiovascular disease, and liver disease, have become increasingly prevalent around the world. As an alternative to bariatric surgery, glucagon-like peptide 1 (GLP-1) receptor agonists have been at the forefront of weight loss medication to combat these metabolic complications. Recently, there has been an exciting rapid emergence of new weight loss medications that combine GLP-1 receptor (GLP-1R) agonists with other gut- and pancreatic-derived hormones, such as glucose-dependent insulinotropic polypeptide (GIP) and glucagon (GCG) receptor agonists. Dual-agonist (GLP-1/GIP and GLP-1/GCG) and tri-agonist (GLP-1/GIP/GCG) administration generally result in greater weight loss, reduction of blood sugar and lipid levels, restoration of tissue function, and improvement in whole-body substrate metabolism compared to when GLP-1R agonists are used alone. The aim of this review is to summarize the recent literature of both preclinical and clinical studies on how these emerging gut-peptide therapies further improve weight loss and metabolic health outcomes for various metabolic diseases.
科研通智能强力驱动
Strongly Powered by AbleSci AI